Managed Markets Market Research
Biomarkers and Surrogate Endpoints in Drug Development Technical and Regulatory Considerations Biomarkers and Surrogate Endpoints in Drug Development Technical.
1 The TRICARE-MHS Benefits Development Process: Advances in Medicine and the NDAA TMA Lead Agent & Directors Summer Meeting August 13-15, 2002.
1 Understanding the TRICARE Medical Benefits Program ____________________________.
